A multicenter, open-label phase II study to evaluate the efficacy and safety of pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC)

被引：0
|
作者：
Zhang, X. [1 ]
Cui, J. [1 ]
Quan, M. [2 ]
Zhang, T. [3 ]
Cao, D. [4 ]
Li, Z. [5 ]
Yang, D. T. C. [6 ]
Zhu, X. [6 ]
Chen, Y. [6 ]
Liang, P. [6 ]
Yao, L. [6 ]
Wang, L. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Renji Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China
[2] Tongji Univ, Dept Oncol, Shanghai East Oriental Hosp, Shanghai, Peoples R China
[3] Huazhong Univ Sci & Technol, Dept Oncol, Union Hosp Tongji Med Coll, Wuhan, Peoples R China
[4] Sichuan Univ, Abdominal Oncol, West China Hosp, Chengdu, Peoples R China
[5] Harbin Med Univ, Dept Oncol, Canc Hosp, Harbin, Peoples R China
[6] Abbisko Therapeut Co Ltd, Clin Dev, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1533TiP
引用
收藏
页码：S934 / S935
页数：2
相关论文
共 50 条
  • [1] A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC).
    Liu, Dan
    Shen, Lin
    Ananda, Sumitra
    Cao, Dan
    Han, Catherine HyeWon
    Coward, Jermaine
    Chao, Yee
    Li, Wei
    Dass, Prashanth Hari
    Hsu, Chih-Hung
    Nagrial, Adnan
    Huang, Yuan
    Ganju, Vinod
    Chen, Xiaobing
    Cohen, Deirdre J.
    Kumar, Rajiv
    Bai, Li-Yuan
    Yuan, Ying
    Chiu, Tai-Jan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study
    Naing, Aung
    Mahipal, Amit
    Javle, Milind
    Wang, Judy
    Bauer, Todd M.
    Bajor, David L.
    Elias, Anthony D.
    Shields, Anthony
    Davis, Elizabeth
    Chawla, Sant
    Safran, Howard
    Powderly, John D.
    D'Amato, Gina
    Meyer, Christian F.
    Tang, Xiongwen
    Yao, Sheng
    Keegan, Patricia
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2025, 8 (01) : 71 - 81
  • [3] An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
    von Tresckow, Bastian
    Morschhauser, Franck
    Ribrag, Vincent
    Topp, Max S.
    Chien, Caly
    Seetharam, Shobha
    Aquino, Regina
    Kotoulek, Sonja
    de Boer, Carla J.
    Engert, Andreas
    CLINICAL CANCER RESEARCH, 2015, 21 (08) : 1843 - 1850
  • [4] OPTIMIZE-1, AN OPEN-LABEL PHASE 1B/2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAZALIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
    de Coana, Yago Pico
    Smith, Karin Enell
    Falt, Anette
    Flardh, Maria
    Ellmark, Peter
    Cassier, Philippe
    van Laethem, Jean-Luc
    Carlsson, Malin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A567 - A567
  • [5] Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial
    Melisi, Davide
    Zecchetto, Camilla
    Merz, Valeria
    Malleo, Giuseppe
    Landoni, Luca
    Quinzii, Alberto
    Casalino, Simona
    Fazzini, Federica
    Gaule, Marina
    Pesoni, Camilla
    Casetti, Luca
    Esposito, Alessandro
    Marchegiani, Giovanni
    Piazzola, Cristiana
    D'Onofrio, Mirko
    de Robertis, Riccardo
    Gabbrielli, Armando
    Bernardoni, Laura
    Crino, Stefano F.
    Pietrobono, Silvia
    Luchini, Claudio
    Aliberti, Camillo
    Martignoni, Guido
    Milleri, Stefano
    Butturini, Giovanni
    Scarpa, Aldo
    Salvia, Roberto
    Bassi, Claudio
    EUROPEAN JOURNAL OF CANCER, 2024, 196
  • [6] An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naive patients (pts) with hormone refractory prostate cancer (HRPC)
    de Bono, JS
    Bellmunt, J
    Droz, JP
    Miller, K
    Zugmaier, G
    Sternberg, C
    Gimenez, V
    Parker, C
    Mason, M
    Graham, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 405S - 405S
  • [7] Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study
    Srimuninnimit, Vichien
    Sriuranpong, Virote
    Suwanvecho, Suthida
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (03) : 255 - 260
  • [8] First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors.
    Falchook, Gerald Steven
    Liang, Yan
    Harvey, R. Donald
    Fu, Siqing
    Weitao, Yao
    Qin, Yan-Ru
    Zhang, Xiaojing
    Henry, Jason Timothy
    Zou, Qingping
    Shan, Boyao
    Liang, Pan
    Wang, Chen
    Li, Wenjia
    Pamuklar, Zehra Nurgul
    Pei, Yi
    Chang, Zhiwei
    Wang, Jiaqiang
    Piha-Paul, Sarina A.
    Bhave, Manali A.
    Yin, Yongmei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors
    Sun, Yuping
    Yu, Jinming
    Tolcher, Anthony W.
    Albany, Costantine
    Chaudhry, Arvind
    Dang, Qi
    Ye, Leiguang
    Yang, Fang
    Liu, Baogang
    Sun, Longhua
    Tang, Jianjun
    Xu, Lei
    Zhu, Xiangyang
    Yang, Yongmin
    Yang, Yang
    Zhan, Yifan
    Li, Benke
    Hou, Kexin
    Zheng, Yang, Sr.
    Wang, Jingjing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] A phase Ib/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics/pharmacodynamics of avb3/5 integrin and neuropilin-1 targeting peptide LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma
    Xu, Jianming
    Niu, Zuoxing
    Bai, Yuxian
    Qiu, Wensheng
    Cui, Jiuwei
    Qu, Xiujuan
    Wu, Zheng
    Zha, Yong
    Zhang, Tao
    Cheng, Wei
    Han, Cuicui
    Si, Meimei
    Li, Lingyan
    Kang, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345